✦ LIBER ✦

Use of cytomegalovirus antigenemia as a marker for preemptive treatment

✍ Scribed by L Guirado; M.A Herreros; J.M Muñoz; N Rabella; C Facundo; I Agraz; M Dı́az; J.M Diaz; F Durán; R Solà

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Definitions of cytomegalovirus disease a

✍ Floria Iberer; Karlheinz Tscheliessnigg; Gabriele Halwachs; Peter Rehak; Andre W 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 710 KB

Definitions of cytomegalovirus disease a

✍ Florian Iberer; Karlheinz Tscheliessnigg; Gabriele Halwachs; Peter Rehak; Andre 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 683 KB

Use of the cytomegalovirus pp65 antigene

✍ B.H. Tan; N.L. Chlebicka; J.G. Hong Low; T.Y.R. Chong; K.P. Chan; Y.T. Goh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 170 KB

Preemptive therapy for the prevention of

✍ M Villa; E Lage; S Ballesteros; E Cañas; M Sánchez; A Ordóñez; J.M Borrego; R Hi 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 100 KB

The Effects of Preemptive Therapy Using

✍ Saracino, A.; Colucci, R.; Latorraca, A.; Muscaridola, N.; Procida, C.; Di Noia, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 222 KB

Cytomegalovirus-specific B cell activati

✍ M. Segondy; J. P. Vendrell; J. Reynes; M. F. Huguet; B. Albat; J. Ducos; J. C. N 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 672 KB